Novocure (NASDAQ:NVCR) shares surged over 30% in extended trading Wednesday following FDA approval of its Optune Pax device for locally advanced pancreatic cancer. The wearable system, used alongside chemotherapy drugs gemcitabine and nab-paclitaxel, employs Tumor Treating Fields (TTFields) to disrupt cancer cell division while sparing healthy tissue. Investors reacted strongly to the breakthrough, with the stock climbing as high as $189.99—a 30% gain—amid speculation about expanded market access.

The approval stems from Phase 3 PANOVA-3 trial results, which demonstrated delayed pain progression and improved one-year survival rates compared to chemotherapy alone. Safety profiles were deemed similar between treatment arms, addressing prior concerns about adverse effects. With pancreatic cancer ranking as the 10th leading cause of cancer death globally, the device’s non-invasive approach could reshape treatment paradigms.

Novocure’s stock has already gained 157% year-to-date, reflecting broader optimism about its oncology pipeline. Analysts note the approval positions the company as a leader in targeted cancer therapies, though long-term success hinges on real-world adoption and reimbursement negotiations. The FDA’s accelerated review process underscores the device’s clinical urgency in a disease with limited therapeutic options.

This milestone reinforces Novocure’s strategic focus on neurological and oncological applications, with CEO Dr. Patrick Hoopes stating the technology "redefines standard care." Competitors like Biogen and Roche may now accelerate their own TTFields research, intensifying market competition in precision oncology.